Skip to content
Open access

Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)

Aug 2026 · ESMO real world data and digital oncology · Vol 13, pp. 100762 · 0 citations · 16 references
Medicine

TL;DR

Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice and longer follow-up is needed to establish how these reductions affect overall efficacy.

Abstract

Background Abemaciclib plus endocrine therapy improves outcomes in high-risk hormone receptor-positive, HER2-negative early breast cancer (EBC) in monarchE, but real-world tolerability, dose modification, and treatment persistence in routine UK practice remain incompletely characterised. Patients and methods A retrospective, multicentre study across 21 NHS Trusts of adults with high-risk EBC initiating adjuvant abemaciclib. The primary endpoint was treatment duration, whereas secondary endpoints included dose modifications, discontinuations, and toxicity profiles. Results The cohort comprised 1026 patients (median age 54 years, range 22-87); 82.9% were Caucasian. Median abemaciclib duration was 15.5 months (range 0.2-24), 25.3% completed 24 months, and 54.9% remained on treatment at data cut-off. Overall, 19.7% discontinued abemaciclib, most commonly due to toxicity (15.9%), and 3.8% discontinued for disease progression. Dose modifications were frequent: 64.6% required ≥1 dose reduction, and 25.2% required ≥2 reductions. Common adverse events were diarrhoea (76.4%, grade ≥3 5.8%), neutropenia (43.4%, grade ≥3 8.2%), anaemia (33.2%, grade ≥3 0.3%), and transaminitis (17.2%, grade ≥3 1.8%). Acute kidney injury occurred in 21.6% (grade ≥3 0.4%), including one fatal case. Increasing diarrhoea and neutropenia grades were associated with first dose reduction; in multivariable analyses, grade ≥3 diarrhoea [adjusted odds ratio (OR) 7.62, 95% confidence interval (CI) 3.44-16.87, P < 0.001] and grade ≥3 neutropenia (adjusted OR 3.87, 3.87, 95% CI 2.11-7.11, P < 0.001) independently predicted dose reduction. Conclusions Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice. Proactive toxicity management is vital to sustain treatment exposure, but longer follow-up is needed to establish how these reductions affect overall efficacy.

Read PDF

Similar papers

Open access Sep 2026

Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study

Background and purpose Abemaciclib in addition to adjuvant endocrine therapy for hormone receptor positive (HR+) breast cancer improves disease free survival (IDFS) and overall survival (OS). However, treatment-related adverse events may lead to early discontinuation. Sahlgrenska University Hospital implemented a gradu...

Carl Rosander, K. Larsson, Per Karlsson · 0 citations
Open access Sep 2026

Non-inferior survival and enhanced longevity with initial low-dose versus full-dose enzalutamide: a single-centre real-world prostate cancer study

Background: Prostate cancer enzalutamide treatment is approved at a standard dose of 160 mg daily. Concerns for real-world patients -- older and more fragile than those enrolled in clinical trials -- have prompted consideration of initiating treatment with lower doses, but the long-term efficacy of this approach remain...

O. Gorobets, V. Vinh-Hung · 0 citations
Open access Sep 2026

Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study

In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.

B. Sharaf, T. Al-Batsh, Suhaib Khater et al. · 0 citations
Open access Sep 2026

Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study

The temporal findings support continued surveillance throughout therapy but do not establish a phase-specific monitoring strategy, and Ibrutinib was associated with substantial toxicity and frequent treatment modification in routine clinical practice.

Wid M. Alyamani, Attiah Khobrani, Fawaz O. Alenazy et al. · 0 citations
Open access Aug 2026

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Fruquintinib demonstrated feasible effectiveness and manageable toxicity in Japanese patients with mCRC and proteinuria was a major determinant of treatment feasibility and frequently led to early dose modification.

Shohei Udagawa, Chihiro Ishizuka, H. Osumi et al. · 0 citations
Sep 2026

Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.

BACKGROUND Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially. OBJECTIVE To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort of consecu...

D. D. Shapiro, D. Roadman, V. Master et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.